Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
RevMab
anti-CPS1 (human), Rabbit Monoclonal (RM395)
Product Details | |
---|---|
Synonyms | Carbamoyl-phosphate Synthase 1; CPSase1 |
Product Type | Recombinant Antibody |
Properties | |
Clone | RM395 |
Isotype | Rabbit IgG |
Source/Host | Rabbit |
Immunogen/Antigen | A peptide corresponding to Human CPS1. |
Application |
Immunohistochemistry (IHC): 1:100-1:200 dilution |
Crossreactivity | Human |
Specificity |
This antibody reacts to human CPS1. |
Purity | Protein A purified. |
Purity Detail | Protein A affinity purified from an animal origin-free culture supernatant. |
Concentration | N/A |
Formulation | Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide. |
Isotype Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Accession Number | P31327 |
Declaration | Manufactured by RevMab Biosciences. |
Shipping and Handling | |
Shipping | BLUE ICE |
Long Term Storage | -20°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
Carbamoyl phosphate synthetase I (CPS1 or CPSI) is a ligase enzyme located in the mitochondria involved in the production of urea. It transfers an ammonia molecule from glutamine or glutamate to a molecule of bicarbonate that has been phosphorylated by a molecule of ATP. The resulting carbamate is then phosphorylated with another molecule of ATP. The resulting molecule of carbamoyl phosphate leaves the enzyme. This reaction is the first committed step of the urea cycle, which is important in the removal of excess urea from cells. Mutations in this gene have been associated with carbamoyl phosphate synthetase 1 deficiency (CPS1D), susceptibility to persistent pulmonary hypertension and susceptibility to venoocclusive disease after bone marrow transplantation.